|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MICAL1 |
Gene summary for MICAL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MICAL1 | Gene ID | 64780 |
| Gene name | microtubule associated monooxygenase, calponin and LIM domain containing 1 | |
| Gene Alias | MICAL | |
| Cytomap | 6q21 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q8TDZ2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64780 | MICAL1 | P2T-E | Human | Esophagus | ESCC | 2.36e-08 | 8.02e-02 | 0.1177 |
| 64780 | MICAL1 | P8T-E | Human | Esophagus | ESCC | 8.27e-06 | 2.75e-02 | 0.0889 |
| 64780 | MICAL1 | P10T-E | Human | Esophagus | ESCC | 1.94e-03 | 4.63e-02 | 0.116 |
| 64780 | MICAL1 | P12T-E | Human | Esophagus | ESCC | 6.57e-09 | 9.26e-02 | 0.1122 |
| 64780 | MICAL1 | P16T-E | Human | Esophagus | ESCC | 1.11e-47 | 9.16e-01 | 0.1153 |
| 64780 | MICAL1 | P21T-E | Human | Esophagus | ESCC | 1.83e-21 | 2.38e-01 | 0.1617 |
| 64780 | MICAL1 | P24T-E | Human | Esophagus | ESCC | 1.68e-11 | 1.74e-01 | 0.1287 |
| 64780 | MICAL1 | P27T-E | Human | Esophagus | ESCC | 8.56e-03 | 1.07e-01 | 0.1055 |
| 64780 | MICAL1 | P28T-E | Human | Esophagus | ESCC | 9.90e-13 | 8.50e-02 | 0.1149 |
| 64780 | MICAL1 | P31T-E | Human | Esophagus | ESCC | 2.56e-10 | 1.00e-01 | 0.1251 |
| 64780 | MICAL1 | P32T-E | Human | Esophagus | ESCC | 2.66e-12 | 1.92e-01 | 0.1666 |
| 64780 | MICAL1 | P37T-E | Human | Esophagus | ESCC | 3.14e-03 | 1.23e-01 | 0.1371 |
| 64780 | MICAL1 | P48T-E | Human | Esophagus | ESCC | 4.48e-02 | 3.92e-02 | 0.0959 |
| 64780 | MICAL1 | P52T-E | Human | Esophagus | ESCC | 6.07e-09 | 1.29e-01 | 0.1555 |
| 64780 | MICAL1 | P56T-E | Human | Esophagus | ESCC | 7.86e-11 | 1.68e+00 | 0.1613 |
| 64780 | MICAL1 | P57T-E | Human | Esophagus | ESCC | 2.94e-03 | 4.17e-02 | 0.0926 |
| 64780 | MICAL1 | P75T-E | Human | Esophagus | ESCC | 6.38e-03 | 4.90e-02 | 0.1125 |
| 64780 | MICAL1 | P76T-E | Human | Esophagus | ESCC | 1.42e-04 | 1.01e-01 | 0.1207 |
| 64780 | MICAL1 | P89T-E | Human | Esophagus | ESCC | 1.58e-02 | 3.58e-01 | 0.1752 |
| 64780 | MICAL1 | P104T-E | Human | Esophagus | ESCC | 1.05e-03 | 2.70e-01 | 0.0931 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:0010563111 | Esophagus | ESCC | negative regulation of phosphorus metabolic process | 274/8552 | 442/18723 | 2.32e-12 | 9.41e-11 | 274 |
| GO:0045936111 | Esophagus | ESCC | negative regulation of phosphate metabolic process | 273/8552 | 441/18723 | 3.18e-12 | 1.25e-10 | 273 |
| GO:2000116111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity | 158/8552 | 235/18723 | 1.67e-11 | 5.90e-10 | 158 |
| GO:0043281111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 143/8552 | 209/18723 | 2.12e-11 | 7.31e-10 | 143 |
| GO:003298416 | Esophagus | ESCC | protein-containing complex disassembly | 151/8552 | 224/18723 | 3.45e-11 | 1.15e-09 | 151 |
| GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
| GO:0001933111 | Esophagus | ESCC | negative regulation of protein phosphorylation | 213/8552 | 342/18723 | 3.54e-10 | 9.76e-09 | 213 |
| GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
| GO:2000117110 | Esophagus | ESCC | negative regulation of cysteine-type endopeptidase activity | 63/8552 | 86/18723 | 1.84e-07 | 2.88e-06 | 63 |
| GO:0043154110 | Esophagus | ESCC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 58/8552 | 78/18723 | 2.38e-07 | 3.61e-06 | 58 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:005101727 | Esophagus | ESCC | actin filament bundle assembly | 100/8552 | 157/18723 | 3.87e-06 | 4.17e-05 | 100 |
| GO:006157227 | Esophagus | ESCC | actin filament bundle organization | 101/8552 | 161/18723 | 9.22e-06 | 8.82e-05 | 101 |
| GO:000815420 | Esophagus | ESCC | actin polymerization or depolymerization | 130/8552 | 218/18723 | 2.19e-05 | 1.88e-04 | 130 |
| GO:0045861111 | Esophagus | ESCC | negative regulation of proteolysis | 195/8552 | 351/18723 | 1.13e-04 | 7.85e-04 | 195 |
| GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
| GO:00436245 | Esophagus | ESCC | cellular protein complex disassembly | 78/8552 | 136/18723 | 4.00e-03 | 1.62e-02 | 78 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MICAL1 | SNV | Missense_Mutation | c.1438N>C | p.Asp480His | p.D480H | Q8TDZ2 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD | |
| MICAL1 | SNV | Missense_Mutation | c.2889N>C | p.Glu963Asp | p.E963D | Q8TDZ2 | protein_coding | tolerated(0.37) | benign(0.046) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MICAL1 | SNV | Missense_Mutation | rs757913471 | c.272N>C | p.Gly91Ala | p.G91A | Q8TDZ2 | protein_coding | tolerated(0.13) | benign(0.014) | TCGA-D8-A1X7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
| MICAL1 | SNV | Missense_Mutation | c.2818G>A | p.Glu940Lys | p.E940K | Q8TDZ2 | protein_coding | deleterious(0) | benign(0.236) | TCGA-E2-A1IE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| MICAL1 | insertion | Nonsense_Mutation | novel | c.2756_2757insTACATGAACCGGGAAGGT | p.Ser919_Gly920insThrTerThrGlyLysVal | p.S919_G920insT*TGKV | Q8TDZ2 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| MICAL1 | insertion | Frame_Shift_Ins | novel | c.3072_3073insATGTGTCATGCAAGCCTCATGATCTCAGA | p.Gln1025MetfsTer20 | p.Q1025Mfs*20 | Q8TDZ2 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MICAL1 | insertion | In_Frame_Ins | novel | c.2289_2290insGAGACG | p.His763_Phe764insGluThr | p.H763_F764insET | Q8TDZ2 | protein_coding | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MICAL1 | insertion | In_Frame_Ins | novel | c.2288_2289insAGAGCTGAGAAGAAGAAC | p.His763delinsGlnGluLeuArgArgArgThr | p.H763delinsQELRRRT | Q8TDZ2 | protein_coding | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MICAL1 | insertion | In_Frame_Ins | novel | c.2648_2649insTCTACAAGGAAAAAGGCAGAG | p.Ala883_Met884insLeuGlnGlyLysArgGlnSer | p.A883_M884insLQGKRQS | Q8TDZ2 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| MICAL1 | SNV | Missense_Mutation | rs137916380 | c.1988N>A | p.Arg663Gln | p.R663Q | Q8TDZ2 | protein_coding | tolerated(0.07) | benign(0.178) | TCGA-JX-A5QV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |